Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Leases (2022 - 2025)

Taysha Gene Therapies' Current Leases history spans 4 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Current Leases changed N/A year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, changed N/A, while the annual FY2024 figure was $1.9 million, 14.03% up from the prior year.
  • Current Leases for Q3 2025 was $1.7 million at Taysha Gene Therapies, down from $1.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.9 million in Q4 2024 and bottomed at $1.5 million in Q4 2022.
  • The 4-year median for Current Leases is $1.7 million (2023), against an average of $1.7 million.
  • The largest annual shift saw Current Leases rose 8.22% in 2023 before it grew 14.03% in 2024.
  • A 4-year view of Current Leases shows it stood at $1.5 million in 2022, then rose by 8.22% to $1.6 million in 2023, then rose by 14.03% to $1.9 million in 2024, then dropped by 11.13% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Current Leases are $1.7 million (Q3 2025), $1.8 million (Q1 2025), and $1.9 million (Q4 2024).